Laureate Pharma and Neoprobe Corporation Announce Manufacturing Alliance
Laureate Pharma, Inc. Logo. (PRNewsFoto/Laureate Pharma, Inc.)
PRINCETON, NJ UNITED STATES
- Laureate to Manufacture Neoprobe's RIGScan(R) CR Monoclonal Antibody Product -
DUBLIN, Ohio and PRINCETON, N.J., Sept. 8 /PRNewswire/ -- Neoprobe Corporation (OTC Bulletin Board: NEOP), a diversified developer of innovative oncology surgical and diagnostic products and Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that they have entered into a Biopharmaceutical Development and Manufacturing Agreement. Under this agreement, Laureate will assist in the development and production of Neoprobe's murine monoclonal antibody CC49 called RIGScan((R)) CR, a tumor-specific targeting agent initially intended for use in treatment of colorectal cancer. Terms of the development and manufacturing agreement were not disclosed.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )
"We are delighted that Neoprobe has selected Laureate Pharma as their development and manufacturing partner," said Robert J. Broeze, Ph. D., President & Chief Executive Officer of Laureate Pharma. "We will work closely in partnership with the Neoprobe biotech team and assist them in driving their product from development into the clinic."
"Laureate Pharma has an established track record in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials," said David Bupp, President & Chief Executive Officer of Neoprobe. "This agreement will allow us to leverage Laureate's expertise and infrastructure while we seek to establish RIGScan((R)) CR as an improvement in the treatment for colorectal cancer.
About Laureate Pharma
Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Dan Leone, Vice President, Business Development at 609-919-3300, or info@laureatepharma.com or visit www.laureatepharma.com.
About Neoprobe
Neoprobe is a biomedical company located in Dublin, Ohio focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek( )and RIGScanCR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. For more information, contact Brent Larson, Chief Financial Officer at 614-822-2330, or info@neoprobe.com or visit www.neoprobe.com
PRINCETON, NJ UNITED STATES
- Laureate to Manufacture Neoprobe's RIGScan(R) CR Monoclonal Antibody Product -
DUBLIN, Ohio and PRINCETON, N.J., Sept. 8 /PRNewswire/ -- Neoprobe Corporation (OTC Bulletin Board: NEOP), a diversified developer of innovative oncology surgical and diagnostic products and Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that they have entered into a Biopharmaceutical Development and Manufacturing Agreement. Under this agreement, Laureate will assist in the development and production of Neoprobe's murine monoclonal antibody CC49 called RIGScan((R)) CR, a tumor-specific targeting agent initially intended for use in treatment of colorectal cancer. Terms of the development and manufacturing agreement were not disclosed.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )
"We are delighted that Neoprobe has selected Laureate Pharma as their development and manufacturing partner," said Robert J. Broeze, Ph. D., President & Chief Executive Officer of Laureate Pharma. "We will work closely in partnership with the Neoprobe biotech team and assist them in driving their product from development into the clinic."
"Laureate Pharma has an established track record in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials," said David Bupp, President & Chief Executive Officer of Neoprobe. "This agreement will allow us to leverage Laureate's expertise and infrastructure while we seek to establish RIGScan((R)) CR as an improvement in the treatment for colorectal cancer.
About Laureate Pharma
Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Dan Leone, Vice President, Business Development at 609-919-3300, or info@laureatepharma.com or visit www.laureatepharma.com.
About Neoprobe
Neoprobe is a biomedical company located in Dublin, Ohio focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek( )and RIGScanCR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. For more information, contact Brent Larson, Chief Financial Officer at 614-822-2330, or info@neoprobe.com or visit www.neoprobe.com
posted by Ben Blanquera at
12:36 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home